On May 21, 2026 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, reported that management will participate in the following investor conferences in June.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference
Date: Thursday, June 4, 2026
Fireside Chat: 3:10 p.m. ET
Location: New York, NY

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Chat: 9:20 a.m. ET
Location: Miami, FL

A live webcast of the presentation will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conferences.

(Press release, CytomX Therapeutics, MAY 21, 2026, View Source [SID1234665924])

On May 21, 2026 Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, reported positive preclinical data featured in an online abstract released in connection with the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2026 highlighting synergistic cytotoxic activity of AKTX-101 in combination with KRAS inhibition in KRAS-mutated pancreatic cancer models. Access the abstract here.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data further expands the potential opportunity for Akari’s lead TROP2-targeting ADC, AKTX-101, and its proprietary RNA spliceosome-modulating payload beyond the Company’s current Phase 1 development plan and supports the broader applicability of targeting RNA splicing as a potential way to treat difficult-to-treat KRAS-driven cancers.

The ASCO (Free ASCO Whitepaper) abstract evaluated the activity of AKTX-101 in combination with adagrasib, a KRAS inhibitor, across pancreatic cancer cell lines harboring KRAS G12D and KRAS G12C. In these studies, the combination of AKTX-101 and adagrasib demonstrated synergistic cell killing in KRAS mutant cell lines driven by G12C and G12D. This synergistic inhibition was not observed with the comparator first-in-class topoisomerase I-targeting TROP2 ADCs. Instead, these ADCs exhibited antagonism when paired with adagrasib. These results suggest that AKTX-101 synergy with KRAS inhibitor may be linked to the novel biology of PH1 targeting RNA splicing. The synergy was explained by PH1’s unique ability target pre-mRNA transcripts for degradation, including those bearing KRAS mutations driving these cancer models.

"KRAS has long been considered one of oncology’s most important but difficult targets, and while recent KRAS inhibitors have represented meaningful progress, there remains a significant opportunity to further enhance activity and broaden therapeutic impact," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "These data suggest that our PH1 RNA splicing modulator payload may offer a fundamentally differentiated mechanism capable of enhancing KRAS inhibitor activity in ways not observed with conventional ADC payloads. We believe this represents an exciting opportunity not only for AKTX-101, but potentially for RNA splicing modulation as a new therapeutic strategy across KRAS-driven tumors."

Dr. Satyajit Mitra, Executive Director and Head of Oncology, stated, "Historically, KRAS mutations have been incredibly difficult to drug, and one may need to approach this problem with drugs of different modalities and mechanisms of action. AKTX 101 synergy with an approved drug, like adagrasib, in an unapproved KRAS setting offers exciting combination possibilities. The PH1 spliceosome modulator payload ADC has the potential to unlock efficacy of cancer therapeutics in cancers with oncogene dependency. We have previously demonstrated combination with AR-v7 oncogenes with enzalutamide and now KRAS oncogenes with adagrasib."

The data featured in the ASCO (Free ASCO Whitepaper) 2026 online abstract build upon Akari’s previously reported AACR (Free AACR Whitepaper) 2026 findings demonstrating differentiated cytotoxicity and superior potency of AKTX-101 versus current TROP2 ADCs utilizing Topoisomerase I inhibitor payloads across multiple tumor models, including bladder, lung (including KRAS G12V mutated NSCLC) and breast cancers.

Akari’s lead program, AKTX-101, is a TROP2-targeting ADC powered by the Company’s proprietary PH1 RNA spliceosome-modulating payload. Unlike traditional ADC payloads that primarily rely on microtubule or DNA-damaging mechanisms, PH1 is designed to disrupt RNA splicing within cancer cells while also activating innate and adaptive immune responses.

Akari has initiated IND-enabling studies for AKTX-101 and is targeting initiation of a Phase 1 first-in-human clinical trial by mid-2027.

For more information about the ASCO (Free ASCO Whitepaper) Annual Meeting 2026, please visit www.asco.org.

(Press release, Akari Therapeutics, MAY 21, 2026, View Source [SID1234665940])

On May 21, 2026 AbbVie (NYSE: ABBV) reported that it will present new data at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago demonstrating the depth and breadth of its oncology pipeline. The data will be shared through multiple oral presentations and posters spanning solid tumors and blood cancer indications.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Collectively, these presentations highlight AbbVie’s continued focus on attacking cancer from inside and outside the cell, supported by sustained investment in its expanding antibody‑drug conjugate (ADC) platform, including Topoisomerase I inhibitor (Top1i)–based ADCs and its T‑cell engager (TCE) portfolio.

"Our oncology pipeline is intentionally designed to address the complexity and heterogeneity of cancer biology through a diversified portfolio of differentiated therapies spanning multiple modalities," said Daejin Abidoye, M.D., vice president, therapeutic area head, oncology, solid tumor and hematology. "The data we are presenting at ASCO (Free ASCO Whitepaper) reflect the strength of this strategy, including continued momentum with our ADC programs in solid tumors and validation of immune-based approaches, such as etentamig, being investigated as a next-generation TCE in multiple myeloma. These results underscore our commitment to advancing assets with distinct scientific approaches aimed to address critical unmet patient needs."

Key findings presented include:

Data from AbbVie’s Top1i ADCs Across Solid Tumors:

Metastatic castration-resistant prostate cancer (mCRPC): A first-in-human Phase 1 study (NCT06318273) evaluating ABBV-969, a potential first-in-class bispecific ADC targeting PSMA/STEAP1, in heavily pretreated patients with mCRPC, demonstrated a confirmed objective response rate (ORR) of 45% among 29 patients with RECIST-evaluable disease. At active dose levels, 67% of patients achieved at least a 50% reduction in prostate-specific antigen (PSA50), with 28% achieving PSA90 responses. The safety profile was manageable in heavily pretreated patients with mCRPC.1 Additional findings to be presented at the meeting.
Small cell lung cancer (SCLC): In Phase 1 data (NCT05599984) of ABBV-706 (SEZ6-directed ADC) in the monotherapy cohort (n=17), SCLC patients receiving ABBV-706 at the recommended Phase 3 dose of 1.8 mg/kg as a second-line therapy achieved an objective response rate (ORR) of 82%— promising data in a disease where prognosis remains poor. The safety profile was comparable with previously reported data.2 Additional findings and updated data will be presented at the meeting. The findings support continued evaluation of ABBV-706 in SCLC.
Platinum-resistant ovarian cancer (PROC) and head and neck squamous cell carcinoma (HNSCC): Data from a Phase 1 basket study of Telisotuzumab adizutecan (Temab-A), a next-generation c-Met–directed ADC, demonstrated antitumor activity of Temab-A monotherapy in biomarker unselected PROC (NCT06084481) and HNSCC (NCT06084481) patients.3,4
Additional observations in c-Met selected patients, to be presented at the meeting, highlight the potential of Temab-A in this population.3,4
These new data support the potential of Temab-A across an expanding range of solid tumors and patient populations, including previously presented data in lung, colorectal and gastric cancers and across patients with MET-amplification and increased c-Met expression.
Relapsed/refractory multiple myeloma (R/R MM): Data from a Phase 1b study of etentamig (NCT05650632), being investigated as a next-generation B-cell maturation antigen (BCMA) x CD3 T-cell engager, as monotherapy in a cohort of heavily pre-treated BCMA-exposed R/R MM patients will be presented at the meeting.
Etentamig is an investigational BCMA and CD3 bispecific antibody T-cell engager composed of bivalent BCMA-binding domains allowing for high BCMA-avidity and a low-affinity CD3 binding domain.
The data showed that among patients (n=11) that proceeded to etentamig after BCMA-directed CAR-T in the prior line of therapy, an ORR of 64% was achieved. Minimal residual disease (MRD) negativity was observed in 67% (2/3) of evaluable patients who received BCMA-directed therapy in the prior line of therapy. The median duration of response was 13 months. No new safety signals were observed. Despite no step-up dosing (SUD) in this cohort, all cytokine release syndrome (CRS) reported (57%) were grade 1 and 2.5 Additional findings to be presented at the meeting.
Further information on AbbVie clinical trials is available at View Source

Additional details on key presentations are available below, and the full ASCO (Free ASCO Whitepaper) Annual Meeting 2026 abstracts are available here.

Title

Date/Time

Session

Abstract
Number

Etentamig in patients (pts) with
relapsed/refractory multiple
myeloma (RRMM) with prior
exposure to B-cell maturation
antigen (BCMA)-targeted therapy.

Friday,

May 29

5:09-5:21
PM CDT

Oral Presentation

Oral Abstract
Session

Hematologic

Malignancies—
Plasma Cell

Dyscrasia

7508

Phase 1 basket study of
telisotuzumab adizutecan
(Temab-A, ABBV-400), a

c-Met protein-targeting antibody-
drug conjugate: Results from
patients with platinum-resistant
ovarian/primary
epithelial/fallopian tube cancer
(PROC).

Saturday,
May 30

8:42-8:48
AM CDT

Rapid Oral
Abstract Session

Gynecologic
Cancer

5514

A phase 2 randomized study
comparing telisotuzumab
adizutecan monotherapy with
standard of care in patients with
post-adjuvant circulating tumor
DNA-positive colorectal cancer.

Saturday,
May 30

9:00 AM-
12:00 PM
CDT

Poster Board:
447a

Poster Session

Gastrointestinal
Cancer—Colorectal
and Anal

TPS3688

A Phase 2 study of telisotuzumab
adizutecan (ABBV-400; Temab-A)
in patients with advanced solid
tumors harboring MET
amplification.

Saturday,
May 30

1:30-4:30
PM CDT

Poster Board:
293a

Poster Session

Developmental
Therapeutics—
Molecularly
Targeted Agents
and Tumor Biology

TPS3157

Phase 1 basket study of
telisotuzumab adizutecan (ABBV-
400, Temab-A), a c-Met protein-
targeting antibody-drug
conjugate: Results from patients
with head and neck squamous
cell carcinoma (HNSCC).

Saturday,
May 30

1:30-4:30
PM CDT

Poster Board:
484

Poster Session

Head and Neck
Cancer

6027

Telisotuzumab adizutecan
(Temab-A) plus osimertinib (osi)
as 1L treatment for
unresectable/metastatic NSCLC.

Sunday,
May 31

9:00 AM-
12:00 PM
CDT

Poster Board:
451a

Poster Session

Lung Cancer—

Non-Small Cell
Metastatic

TPS8663

Impact of MET amplification
(amp) on telisotuzumab vedotin
(Teliso-V) efficacy and safety in
2L+ non-squamous (NSQ) EGFR
wild-type (WT) NSCLC with c-Met
protein overexpression (OE).

Sunday,
May 31

9:00 AM-
12:00 PM
CDT

Poster Board: 314

Poster Session

Lung Cancer—

Non-Small Cell
Metastatic

8524

AndroMETa-Lung-713: A phase
2/3 study of telisotuzumab
adizutecan (ABBV-400, Temab-A)
vs standard of care (SOC) in
patients with epidermal growth
factor receptor (EGFR)-mutated
non-small cell lung cancer
(NSCLC).

Sunday,
May 31

9:00 AM-
12:00 PM
CDT

Poster Board:
450a

Poster Session

Lung Cancer—

Non-Small Cell
Metastatic

TPS8661

SEZanne: A phase 2 randomized,
open-label, multicenter study to
evaluate the optimal dose, safety,
and efficacy of ABBV-706 in
combination with atezolizumab
(atezo) versus standard of care
(SOC) in patients (pts) with

previously untreated extensive-
stage (ES) small cell lung cancer
(SCLC).

Sunday,
May 31

9:00 AM-
12:00 PM
CDT

Poster Board:
603a

Poster Session

Lung Cancer—Non-
Small Cell Local-
Regional/Small
Cell/Other
Thoracic Cancers

TPS8135

A phase 1, first-in-human (FIH)
study evaluating the safety,
pharmacokinetics, and efficacy of
ABBV-969 in patients with
metastatic castration-resistant
prostate cancer (mCRPC).

Sunday,

May 31

4:42-4:48
PM CDT

Rapid Oral
Abstract Session

Genitourinary

Cancer—Prostate,
Testicular,

and Penile

5014

A single-arm, phase 2 study of
neoadjuvant mirvetuximab
soravtansine and carboplatin for
FRα-expressing advanced-stage
serous epithelial ovarian, fallopian
tube, or primary peritoneal cancer
(M25-231; NCT06890338; GOG-

3115).

Monday,
June 1

9:00 AM-
12:00 PM
CDT

Poster Board:
296b

Poster Session

Gynecologic
Cancer

TPS5633

ABBV-706 as monotherapy and in
combination with budigalimab in
patients with relapsed/refractory
(R/R) small cell lung cancer (SCLC).

Monday,

June 1

3:39-3:51
PM CDT

Oral Presentation

Oral Abstract
Session

Lung Cancer—Non-
Small Cell Local-
Regional/Small
Cell/Other
Thoracic Cancers

8008

Phase 1, first-in-human (FIH)
study evaluating safety and
efficacy of ABBV-706: Results
from patients with high-grade
central nervous system (CNS)
tumors.

Monday,

June 1

1:30-4:30
PM CDT

Poster Board: 406

Poster Session

Central Nervous
System Tumors

2041

A US-based, retrospective,
observational study of biomarker
testing patterns across lines of
therapy in patients with
metastatic colorectal cancer.

N/A

Publication Only

Gastrointestinal
Cancer –
Colorectal and
Anal

e15526

Timing of biomarker testing and
associated clinical outcomes in
ovarian cancer patients: A
retrospective study.

N/A

Publication Only

Gynecologic
Cancer

e17574

Real-world (RW) characteristics
and outcomes in platinum-
resistant ovarian cancer (PROC)
patients treated with
mirvetuximab soravtansine
(MIRV) monotherapy or single-
agent chemotherapy (CTx).

N/A

Publication Only

Gynecologic
Cancer

e17606

Telisotuzumab adizutecan (Temab-A), etentamig, ABBV-969, and ABBV-706 are investigational medicines and are not approved by any health authorities worldwide. The safety and efficacy of these investigational medicines are under evaluation as part of ongoing clinical studies.

U.S. Prescribing Information for AbbVie Medicines

Please see full Prescribing Information for ELAHERE (mirvetuximab soravtansine-gynx)
Please see full Prescribing Information for EMRELIS (telisotuzumab vedotin-tllv)
Please see full Prescribing Information for EPKINLY (epcoritamab -bysp)

(Press release, AbbVie, MAY 21, 2026, View Source [SID1234665956])

On May 21, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported new retrospective data showing that Noetik’s artificial intelligence-based TARIO-2 model identified spatial tumor microenvironment patterns associated with clinical outcomes from routine pretreatment tumor pathology images in patients treated with botensilimab (BOT) plus balstilimab (BAL), Agenus’ investigational next-generation multifunctional, Fc-enhanced anti-CTLA-4 and anti-PD-1 immunotherapy combination.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data will be presented on May 30, 2026, by Ryan Dalton, Ph.D., of Noetik, during a poster session at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting. The presentation, titled "Artificial intelligence foundation model as a predictor of efficacy of next-generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images," evaluated whether Noetik’s TARIO-2 model could analyze standard hematoxylin and eosin (H&E) pathology images to identify spatial tumor microenvironment patterns associated with clinical outcomes following treatment with BOT+BAL.

BOT is an Fc-enhanced anti-CTLA-4 antibody designed to broaden anti-tumor immune activity through effects on T-cell priming, antigen presentation and regulatory T cells within the tumor microenvironment. Given BOT+BAL’s differentiated mechanism and prior observations that clinical activity is not strongly associated with traditional biomarkers such as PD-L1 expression or tumor mutational burden, broader tumor microenvironment-based approaches may be important for identifying patients most likely to benefit.

The analysis included 113 efficacy-evaluable patients treated with BOT+BAL in the C-800-01 Phase 1b trial who had available pretreatment H&E images. Tumor cohorts included microsatellite stable (MSS) metastatic colorectal cancer (mCRC) without active liver metastases, ovarian cancer and sarcomas. The analysis evaluated TARIO-2’s ability to predict clinical endpoints including best overall response and overall survival.

In the MSS mCRC without active liver metastases cohort, TARIO-2 demonstrated statistically significant predictive performance for both best overall response and overall survival. Supportive trends were observed in the ovarian cancer and sarcoma cohorts. In the MSS mCRC without active liver metastases cohort, TARIO-2 also outperformed benchmark pathology foundation models in predicting best overall response and overall survival.

TARIO-2 does not rely on a traditional single-marker biomarker approach. Instead, the model applies AI-based spatial tumor microenvironment analysis to standard H&E pathology images, which are routinely generated during cancer diagnosis and clinical evaluation. By using widely available H&E images, TARIO-2 is designed to extract biologically relevant tumor microenvironment features without requiring more complex tissue-profiling approaches that may be difficult to implement routinely. This approach may support future patient stratification strategies if prospectively validated.

"Routine pathology images are already part of cancer care, but much of the biologic information they contain is difficult to interpret by eye alone," said Ryan Dalton, Ph.D., Senior Computational Scientist at Noetik. "These data suggest that AI-based analysis of pretreatment H&E images may help identify spatial tumor microenvironment patterns associated with clinical benefit from BOT+BAL. The findings support prospective validation of TARIO-2 as a practical, image-based biomarker strategy."

BOT+BAL is being evaluated as a novel immunotherapy combination designed to expand immune activity in tumors that have historically been difficult to treat with conventional immunotherapies. The ability to better understand which patients are most likely to benefit remains an important area of translational research, particularly in tumor types with limited immunotherapy options.

"BOT+BAL is designed to engage the immune system in tumors that have historically been resistant to conventional immunotherapy, through differentiated mechanisms not fully captured by traditional biomarkers such as PD-L1 expression or tumor mutational burden," said Dhan Chand, Ph.D., Vice President of Research at Agenus. "These data represent an important step toward aligning BOT+BAL’s differentiated biology with the patients most likely to benefit. Prospective validation will be an important next step as we continue to advance BOT+BAL clinical development."

The findings support prospective validation of TARIO-2 as an H&E-based biomarker strategy for BOT+BAL, including further evaluation in MSS colorectal cancer and broader solid tumor datasets.

Following the poster session on May 30, 2026, the full poster will be available on the Publications page of the Agenus website.

Presentation Details

Abstract Title: Artificial intelligence (AI) foundation model as a predictor of efficacy of next-generation checkpoint inhibition with botensilimab (BOT) + balstilimab (BAL) in solid tumors using pretreatment H&E images
Abstract No.: 2535
Presenter: Ryan Dalton Ph.D., Sr. Computational Scientist, Noetik
Session Title: Poster Session – Developmental Therapeutics—Immunotherapy
Location: Hall A – Posters and Exhibits
Poster Board: 325
Date/Time: May 30, 2026, 1:30 PM–4:30 PM CDT

(Press release, Agenus, MAY 21, 2026, View Source [SID1234665972])

On May 21, 2026 Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, reported a poster presentation of data from the Phase 1 study of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies treated in the post-checkpoint inhibitor setting will be presented at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place May 29 – June 2, 2026, in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to share the initial clinical data from the dose escalation portion of our ongoing Phase 1 study of CTX-8371 in patients with advanced malignancies treated in the post-checkpoint inhibitor setting at ASCO (Free ASCO Whitepaper)," said Thomas Schuetz, MD, PhD, CEO of Compass and Vice Chairman of the Board of Directors. "Based on the deep, confirmed, and durable responses observed in patients with NSCLC, TNBC and HL, as well as the favorable safety profile, we have initiated cohort expansions in patients with these three malignancies and anticipate reporting additional data in the fourth quarter of 2026."

Details of the presentation are as follows:

Title: Phase 1 Dose Escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition

Presenter: Judy S Wang, MD; Florida Cancer Specialists/Sarah Cannon Research Institute- Sarasota, Sarasota, FL

Date & Time: May 30, 2026 at 1:30-4:30 pm CT

Session: Developmental Therapeutics—Immunotherapy

Abstract number: 2629

Poster Board: 419

Location: McCormick Place Convention Center, Hall A

Data highlights from the poster presentation include:

15 patients completed the dose-limiting toxicity (DLT) evaluation period and had at least one post-baseline disease assessment in the dose escalation cohort of the Phase 1, open-label, first-in-human study evaluating CTX-8371 in patients with metastatic or locally advanced malignancies.
There were three responses: one patient with TNBC achieved > 90% reduction in target tumor lesions, one patient with HL achieved a partial metabolic response, and one patient with NSCLC achieved complete resolution of target lesions after initial pseudo-progression.
At the two highest dose levels (3.0 and 10.0 mg/kg), the overall response rate (ORR) was 33% (2 of 6 evaluable patients). The responses at the two highest dose levels were significantly durable: 10.5+ months for TNBC and 7.5+ months HL. Both of these patients remain on study with continuing durability.
CTX-8371 was well tolerated with no DLTs. All treatment-related adverse events (AEs) were mild Grade 1 or Grade 2, with the exception of one asymptomatic Grade 3 lipase increase.
A copy of the presentation materials can be accessed on the Compass website at View Source once the presentation has concluded.

(Press release, Compass Therapeutics, MAY 21, 2026, View Source [SID1234665988])